Drug reference

pegfilgrastim

Granulocyte Colony-Stimulating Factor · Hematopoietic Agent

Granulocyte Colony-Stimulating FactorHematopoietic Agent

CDSCO approved

EXCRETION

—

not curated

INTERACTIONS

1 major

SEVERE in our sources

PREGNANCY

—

not curated

Top interactions

CladribineSevereDatabaseDDInter

Mechanism

Pegfilgrastim is a pegylated form of G-CSF, providing a prolonged half-life compared to filgrastim. It stimulates granulocyte colony-forming units (CFU-G) to increase neutrophil production and enhances their phagocytic and cytotoxic activities.

Indications

prevention of chemotherapy-induced neutropeniaPrimary prophylaxis of febrile neutropenia (if probability is ≥20%)Primary prophylaxis of febrile neutropenia (if patient has preexisting neutropenia or active infection)Primary prophylaxis of febrile neutropenia (if age >65 years treated for lymphoma with curative intent or other tumors by similar regimens)Primary prophylaxis of febrile neutropenia (if poor performance status)Primary prophylaxis of febrile neutropenia (if extensive prior chemotherapy)Primary prophylaxis of febrile neutropenia (dose-dense regimens in a clinical trial or with strong evidence of benefit)Secondary prophylaxis of febrile neutropenia (if febrile neutropenia occurred in previous cycle)Secondary prophylaxis of febrile neutropenia (if prolonged neutropenia even without fever delays therapy)Mobilize stem cells from marrow in bone marrow or peripheral blood stem cell transplantationHasten myeloid recovery in bone marrow or peripheral blood stem cell transplantation

Dosing

Adult: Fixed dose of 6 mg subcutaneously once per chemotherapy cycle for patients weighing more than 20 kg. Typically administered 24 h after chemotherapy and at least 14 days prior to the next planned chemotherapy dose.